Vivan Therapeutics Launches in Beijing: Revolutionising Cancer Care Through Personalised Treatment
Vivan Therapeutics, a leading UK based company pioneering personalized cancer treatment has expanded to China as Beijing Weiwan Medical Biotechnology Co, Ltd. This strategic expansion brings the UK-based biotech company’s innovative Personal Discovery Process (PDP) and TuMatch clinical decision support software to one of the world’s largest healthcare markets.
Nathan McNally, CEO of P4 Precision Medicine Innovation Center scouted Vivan’s technology and explains, “As our first company landing in The P4 Beijing Innovation Center, Vivan Therapeutics is already providing world class treatment options to patients through leading China medical centers-demonstrating the benefit of UK and China cooperation”.
The company’s revolutionary approach addresses one of oncology’s greatest challenges: finding the right treatment for each individual patient. Traditional cancer treatment often follows a one-size-fits-all approach, but Vivan Therapeutics recognizes that every patient’s tumor is genetically unique and requires a tailored therapeutic strategy.
Vivan Therapeutics’s platform technology, the Personal Discovery Process, was developed in partnership with Mount Sinai Medical Center in New York. This cutting-edge technology creates genetically matched fruit fly models of each patient’s tumor, essentially building a living avatar of the cancer. These personalized models undergo large-scale drug screening to identify novel drug combinations that prove efficacious for that specific patient’s tumor genetics. The platform evaluates all FDA-approved medications, including non-cancer drugs, potentially uncovering unexpected therapeutic combinations that traditional oncology might overlook. This methodology has shown particular promise for hard-to-treat cancers, where conventional treatment options have been exhausted.
AI-driven
QVivan's AI-driven digital health platform represents the next evolution in precision medicine. The technology can rapidly predict effective treatment recommendations, making it highly scalable.
The company has amassed a deep, ever expanding proprietary data set based on whole animal disease modelling coupled with drug screening. This oncology data set provides the basis for TuMatch. Vivan/Weiwan formed a partnership with Beijing based Thorgene to accelerate integration into the healthcare system. Dr. Qian Chen, Co-Founder & Chief Scientist of Beijing based Thorgene comments, “By partnering with Vivan Therapeutics, we can bring their TuMatch™ AI-driven functional genomics platform—capable of testing thousands of drug-gene interactions—into China’s leading oncology centres. Vivian’s rapid, patient-specific drug-screening insights, combined with Thorgene’s nationwide sequencing and clinical validation network, empower Chinese clinicians to choose more effective treatments sooner, improving survival and quality of life for countless cancer patients.”
Vivan’s Founder & CEO Laura Towart commented:
Beijing
This launch signals the beginning of a new era in cancer treatment for Chinese patients, offering hope for more effective, targeted therapies tailored to each person's unique cancer profile.
Our China expansion and local presence provides Vivan Therapeutics with access to a vast patient population and a rapidly advancing healthcare infrastructure that supports innovative treatment approaches.
